Lynk Pharmaceuticals

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
JAK1Small molecule
Atopic DermatitisRheumatoid Arthritis
Phase 2
Pan-JAKSmall molecule
Atopic Dermatitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
ZemprocitinibPhase 3Ankylosing Spondylitis
Est. primary completion 2026-11 · NCT07237568 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 November 2026Filing acceptedZemprocitinibChina accepts the zemprocitinib application in rheumatoid arthritis
CN, NMPA · Lynk Pharmaceuticals · Source ↗
10 April 2026Filing acceptedzemprocitinib (LNK01001)Zemprocitinib NDA accepted by China's NMPA (CDE)
CN, NMPA · Lynk Pharmaceuticals · Source ↗
12 January 2026Topline resultLNK01001 (zemprocitinib)COURAGE-RA (NCT06276998) Phase 3 met its primary endpoint
China · Simcere Pharmaceutical Group · Source ↗
19 November 2025Topline resultLNK01004Phase 2 of topical LNK01004 in atopic dermatitis showed superior efficacy to vehicle at week 8

Financial reports

No financial reports recorded.